Voyager Therapeutics, Inc. (VYGR): Price and Financial Metrics

Voyager Therapeutics, Inc. (VYGR): $6.06

-0.21 (-3.35%)

POWR Rating

Component Grades














  • Value is the dimension where VYGR ranks best; there it ranks ahead of 94.54% of US stocks.
  • The strongest trend for VYGR is in Momentum, which has been heading up over the past 177 days.
  • VYGR ranks lowest in Stability; there it ranks in the 18th percentile.

VYGR Stock Summary

  • Of note is the ratio of VOYAGER THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; merely 16.17% of US stocks have a lower such ratio.
  • For VYGR, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
  • As for revenue growth, note that VYGR's revenue has grown 344.22% over the past 12 months; that beats the revenue growth of 97.22% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VOYAGER THERAPEUTICS INC are RXRX, ADAP, PRTC, CRBU, and TGTX.
  • VYGR's SEC filings can be seen here. And to visit VOYAGER THERAPEUTICS INC's official web site, go to

VYGR Valuation Summary

  • VYGR's EV/EBIT ratio is -9.1; this is 204.6% lower than that of the median Healthcare stock.
  • VYGR's price/earnings ratio has moved down 0.4 over the prior 86 months.

Below are key valuation metrics over time for VYGR.

Stock Date P/S P/B P/E EV/EBIT
VYGR 2022-12-02 3.5 3.1 -14.6 -9.1
VYGR 2022-12-01 3.3 2.9 -13.7 -8.2
VYGR 2022-11-30 3.3 2.9 -13.4 -7.9
VYGR 2022-11-29 3.0 2.7 -12.5 -7.0
VYGR 2022-11-28 3.0 2.7 -12.6 -7.1
VYGR 2022-11-25 3.0 2.7 -12.5 -6.9

VYGR Growth Metrics

    Its 2 year revenue growth rate is now at -73.08%.
  • Its 4 year price growth rate is now at 1.34%.
  • The year over year net income to common stockholders growth rate now stands at -280.07%.
VYGR's revenue has moved down $33,862,000 over the prior 33 months.

The table below shows VYGR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 70.529 10.93 -17.073
2022-06-30 30.925 6.427 -59.834
2022-03-31 31.57 2.195 -70.867
2021-12-31 37.415 -53.525 -71.197
2021-09-30 15.877 -86.697 -92.832
2021-06-30 132.238 -90.728 17.916

VYGR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VYGR has a Quality Grade of D, ranking ahead of 16.57% of graded US stocks.
  • VYGR's asset turnover comes in at 0.071 -- ranking 290th of 681 Pharmaceutical Products stocks.
  • JAGX, SGEN, and OTLC are the stocks whose asset turnover ratios are most correlated with VYGR.

The table below shows VYGR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.071 1 -1.098
2021-06-30 0.541 1 0.193
2021-03-31 0.598 1 0.402
2020-12-31 0.595 1 0.386
2020-09-30 0.634 1 0.362
2020-06-30 0.296 1 -0.420

VYGR Price Target

For more insight on analysts targets of VYGR, see our VYGR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.06 Average Broker Recommendation 1.78 (Moderate Buy)

VYGR Stock Price Chart Interactive Chart >

Price chart for VYGR

VYGR Price/Volume Stats

Current price $6.06 52-week high $10.60
Prev. close $6.27 52-week low $2.60
Day low $6.00 Volume 59,600
Day high $6.36 Avg. volume 400,770
50-day MA $5.66 Dividend yield N/A
200-day MA $6.30 Market Cap 233.96M

Voyager Therapeutics, Inc. (VYGR) Company Bio

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The company was founded in 2013 and is based in Cambridge, Massachusetts.

VYGR Latest News Stream

Event/Time News Detail
Loading, please wait...

VYGR Latest Social Stream

Loading social stream, please wait...

View Full VYGR Social Stream

Latest VYGR News From Around the Web

Below are the latest news stories about VOYAGER THERAPEUTICS INC that investors may wish to consider to help them evaluate VYGR as an investment opportunity.

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee’s entering into employment with Voyager. The inducement awards were approv

Yahoo | November 29, 2022

Voyager Therapeutics Third Quarter 2022 Earnings: Beats Expectations

Voyager Therapeutics ( NASDAQ:VYGR ) Third Quarter 2022 Results Key Financial Results Revenue: US$41.1m (up by US$39.6m...

Yahoo | November 10, 2022

Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 336.84% and 93.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results

- Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs advancing; development candidate selections for lead programs expected Q4 2022 to H1 2023 - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene the

Yahoo | November 8, 2022

Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced it will report third quarter 2022 financial and operating results before the market opens on Tuesday, November 8, 2022. Subsequently, the Company will host a live conference call and webcast at 8:30 a.m. ET to review its financial and operating results. T

Yahoo | November 1, 2022

Read More 'VYGR' Stories Here

VYGR Price Returns

1-mo 26.51%
3-mo -13.92%
6-mo 12.22%
1-year 102.00%
3-year -56.65%
5-year -55.99%
YTD 123.62%
2021 -62.10%
2020 -48.75%
2019 48.40%
2018 -43.37%
2017 30.30%

Continue Researching VYGR

Here are a few links from around the web to help you further your research on Voyager Therapeutics Inc's stock as an investment opportunity:

Voyager Therapeutics Inc (VYGR) Stock Price | Nasdaq
Voyager Therapeutics Inc (VYGR) Stock Quote, History and News - Yahoo Finance
Voyager Therapeutics Inc (VYGR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6184 seconds.